IRIS Accounts Production v26.1.0.640 14486723 Board of Directors Board of Directors 1.1.25 31.12.25 31.12.25 11.5.26 false true false false false true false Auditors Opinion iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh144867232024-12-31144867232025-12-31144867232025-01-012025-12-31144867232023-12-31144867232024-01-012024-12-31144867232024-12-3114486723ns15:EnglandWales2025-01-012025-12-3114486723ns14:USDollar2025-01-012025-12-3114486723ns10:Director12025-01-012025-12-3114486723ns10:Director22025-01-012025-12-3114486723ns10:PrivateLimitedCompanyLtd2025-01-012025-12-3114486723ns10:SmallEntities2025-01-012025-12-3114486723ns10:Audited2025-01-012025-12-3114486723ns10:SmallCompaniesRegimeForDirectorsReport2025-01-012025-12-3114486723ns10:SmallCompaniesRegimeForAccounts2025-01-012025-12-3114486723ns10:FullAccounts2025-01-012025-12-311448672312025-01-012025-12-3114486723ns10:Director42025-01-012025-12-3114486723ns10:RegisteredOffice2025-01-012025-12-3114486723ns5:CurrentFinancialInstruments2025-12-3114486723ns5:CurrentFinancialInstruments2024-12-3114486723ns5:ShareCapital2025-12-3114486723ns5:ShareCapital2024-12-3114486723ns5:FurtherSpecificReserve1ComponentTotalEquity2025-12-3114486723ns5:FurtherSpecificReserve1ComponentTotalEquity2024-12-3114486723ns5:RetainedEarningsAccumulatedLosses2025-12-3114486723ns5:RetainedEarningsAccumulatedLosses2024-12-3114486723ns5:IntangibleAssetsOtherThanGoodwill2025-01-012025-12-3114486723ns5:PatentsTrademarksLicencesConcessionsSimilar2025-01-012025-12-3114486723ns5:PlantMachinery2025-01-012025-12-3114486723ns5:IntangibleAssetsOtherThanGoodwill2025-12-3114486723ns5:PlantMachinery2024-12-3114486723ns5:PlantMachinery2025-12-3114486723ns5:PlantMachinery2024-12-3114486723ns5:WithinOneYearns5:CurrentFinancialInstruments2025-12-3114486723ns5:WithinOneYearns5:CurrentFinancialInstruments2024-12-3114486723ns5:CurrentFinancialInstruments2025-01-012025-12-3114486723ns5:WithinOneYear2025-12-3114486723ns5:WithinOneYear2024-12-3114486723ns5:BetweenOneFiveYears2025-12-3114486723ns5:BetweenOneFiveYears2024-12-3114486723ns5:AllPeriods2025-12-3114486723ns5:AllPeriods2024-12-31
REGISTERED NUMBER: 14486723 (England and Wales)















Financial Statements for the Year Ended 31 December 2025

for

Sapio Sciences UK Limited

Sapio Sciences UK Limited (Registered number: 14486723)

Contents of the Financial Statements
for the Year Ended 31 December 2025










Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 4


Sapio Sciences UK Limited

Company Information
for the Year Ended 31 December 2025







DIRECTORS: Mr G McCall
Mr R A Roda





REGISTERED OFFICE: C/O Aztec Financial Sercives UK Ltd
Forum 4, Solent Business Park
Parkway South, Whiteley
Fareham
Hampshire
PO15 7AD





REGISTERED NUMBER: 14486723 (England and Wales)

Sapio Sciences UK Limited (Registered number: 14486723)

Balance Sheet
31 December 2025

2025 2024
Notes $    $    $    $   
FIXED ASSETS
Intangible assets 5 12,880 -
Tangible assets 6 49,614 31,105
62,494 31,105

CURRENT ASSETS
Debtors 7 4,398,387 2,106,260
Cash at bank 866,741 491,368
5,265,128 2,597,628
CREDITORS
Amounts falling due within one year 8 4,305,366 1,698,364
NET CURRENT ASSETS 959,762 899,264
TOTAL ASSETS LESS CURRENT
LIABILITIES

1,022,256

930,369

PROVISIONS FOR LIABILITIES 9,180 8,269
NET ASSETS 1,013,076 922,100

CAPITAL AND RESERVES
Called up share capital 1 1
Cumulative translation adj 116,780 -
Retained earnings 896,295 922,099
1,013,076 922,100

Sapio Sciences UK Limited (Registered number: 14486723)

Balance Sheet - continued
31 December 2025


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 30 April 2026 and were signed on its behalf by:




Mr G McCall - Director



Mr C A Beckwith - Director


Sapio Sciences UK Limited (Registered number: 14486723)

Notes to the Financial Statements
for the Year Ended 31 December 2025


1. STATUTORY INFORMATION

Sapio Sciences UK Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The presentation currency of the financial statements is the US Dollar ($).


2. STATEMENT OF COMPLIANCE

These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006.

3. ACCOUNTING POLICIES

Basis of preparing the financial statements
The financial statements have been prepared under the historical cost convention.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Intangible assets
Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

Patents and licences are being amortised evenly over their estimated useful life of five years.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off the cost less estimated residual value of each asset over its estimated useful life.
Plant and machinery etc - 33% on cost

Financial instruments
A financial asset or a financial liability is recognised only when the entity becomes a party to the contractual provisions of the instruments.

Basic financial instruments are initially recognised at the transaction price, unless the arrangement constitutes, in effect, a financing transaction, where it is recognised at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.

Debt instruments are subsequently measured at amortised cost.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.


Sapio Sciences UK Limited (Registered number: 14486723)

Notes to the Financial Statements - continued
for the Year Ended 31 December 2025


3. ACCOUNTING POLICIES - continued
Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Hire purchase and leasing commitments
Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

Foreign currency
The Financial Statements have been prepared in US Dollars ('USD'), which is the functional and presentation currency of the Company.

Transactions in foreign currencies are translated into USD using the exchange rates prevailing at the dates of transactions. Non-monetary assets and liabilities measured at historical cost are translated using the exchange rate at the date of the transaction and non-monetary assets and liabilities measured at fair value are measured using an exchange rate when fair value was determined.

At the period end, monetary assets and liabilities denominated in a foreign currency shall be translated by using the closing rate. All exchange gains or losses on settled transactions and unsettled monetary items shall be reported as part of the profit or loss for the period from ordinary activities.

4. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 25 (2024 - 20 ) .

5. INTANGIBLE FIXED ASSETS
Other
intangible
assets
$   
COST
Additions 15,153
At 31 December 2025 15,153
AMORTISATION
Charge for year 2,273
At 31 December 2025 2,273
NET BOOK VALUE
At 31 December 2025 12,880

Sapio Sciences UK Limited (Registered number: 14486723)

Notes to the Financial Statements - continued
for the Year Ended 31 December 2025


6. TANGIBLE FIXED ASSETS
Plant and
machinery
etc
$   
COST
At 1 January 2025 61,906
Additions 48,930
At 31 December 2025 110,836
DEPRECIATION
At 1 January 2025 30,801
Charge for year 30,421
At 31 December 2025 61,222
NET BOOK VALUE
At 31 December 2025 49,614
At 31 December 2024 31,105

7. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2025 2024
$    $   
Trade debtors 2,700,612 733,994
Amounts owed by group undertakings - 847,518
Other debtors 1,697,775 524,748
4,398,387 2,106,260

Other debtors consists of $212,538 (2024: $245,532) relating to prepayments, a balance of $1,200,001 (2024: $183,607) relating to accrued income, a balance of $107,507 (2024: $nil) relating to tax debtor, a balance of $77,936 (2024: $24,175) relating to VAT debtor and a balance of $99,793 (2024: $71,434) relating to various deposits.

8. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2025 2024
$    $   
Trade creditors 164,468 126,420
Amounts owed to group undertakings 1,302,270 142,864
Taxation and social security - 297,523
Other creditors 2,838,628 1,131,557
4,305,366 1,698,364

Other creditors consists of $2,838,628 (2024: $1,131,557) relating to accruals and deferred income.

Sapio Sciences UK Limited (Registered number: 14486723)

Notes to the Financial Statements - continued
for the Year Ended 31 December 2025


9. LEASING AGREEMENTS

Minimum lease payments under non-cancellable operating leases fall due as follows:
2025 2024
$    $   
Within one year 176,903 165,225
Between one and five years 58,968 55,075
235,871 220,300

10. DISCLOSURE UNDER SECTION 444(5B) OF THE COMPANIES ACT 2006

The Report of the Auditors was unqualified.

Jonathan Ward ACA FCCA (Senior Statutory Auditor)
for and on behalf of R. M. Chancellor & Company Limited

11. RELATED PARTY DISCLOSURES

The Company entered into transactions with a fellow wholly owned group company, Sapio Science LLC, during the year. These included the recharge of operating costs and other intercompany transactions such as cash funding support and shared service allocations.

The recharge amounted to $3,401,538 (2024: $5,932,450) based on a 10% markup on costs, consistent with the prior year’s methodology.

At the year end, the Company had a net payable balance of $1,161,306 (2024: $847,517 receivable) due from Sapio Sciences LLC. This balance includes amounts arising from transfer pricing recharges, other intercompany funding and settlements and recharges of shared miscellaneous overheads.

In addition, the Company had transactions with its parent undertaking, Jarvis Parent, LP. At the year end, the Company had a balance payable of $140,964 (2024: $142,864) to Jarvis Parent, LP.

12. ULTIMATE CONTROLLING PARTY

The company is a wholly owned subsidiary of Jarvis Bidco Inc, a company registered in the United States of America whose address is 205 N George St C/O Sapio Sciences Consulting York, PA 17401.

13. CUMULATIVE TRANSLATION ADJUSTMENT

The Company’s functional currency is the British Pound Sterling (GBP), while the parent company reports its consolidated financial statements in U.S. dollars (USD). In accordance with FRS 102 Section 30 - Foreign currency translation, the financial statements of the Company are translated into USD using the following methodology:

Foreign currency transactions are translated at the spot rate on the transaction date.

At each reporting date, monetary items (e.g. debtors and creditors) are retranslated using the closing rate.

Exchange differences on these retranslations, or on the settlement of monetary items, are recognised in profit.

Exchange differences on non-monetary items (usually only arising on settlement) are recorded in the same place (profit or other comprehensive income) as the gain or loss on the item itself.